REFERENCES
- Hogg RS, Rhone SA, Yip B, et al. Antiviral effect of double and triple drug combinations amongst HIV-infected adults: Lessons from the implementation of viral load-driven therapy. AIDS. 1998;12:279.
- Gazzard B, Moyle G. 1998 Revisions to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet. 1998;352:314–316.
- Carpenter CCJ, Cooper DA, Fisch MA, et al. Antiretroviral therapy in adults. JAMA. 2000;283:381.
- Condra JH, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors [letter]. Nature. 1995;374:569–571.
- Merry C, Barry MG, Mulcahy F, et al. The pharmacokinet-ics of combination therapy with nelfinavir plus nevirapine. AIDS. 1998;12:1163–1167.
- Battegay M, Harr T, Sponagel L. Salvage treatment against human immunodeficiency virus. Ann Med. 1999;31:253–260.
- Gulick RM, Katzenstein D, Hu H, et al. Salvage therapy with saquinavir soft gel capsules in combination with ritonavir or nelfinavir and delavirdine, adefovir dipivoxil, or both: ACTG 359. Presented at: Second International Workshop on Salvage Therapy for HIV Infection; May 1999; Toronto. Abstract 020.
- Deeks SG, Grant SM, Symmonds W, et al. Twenty-week HIV RNA response and correlation with baseline pheno-typic drug susceptibility during treatment with a novel quadruple salvage regimen after failure of indinavir combi-nation therapy. Presented at: XIIth International Confer-ence on AIDS; June 1998; Geneva. Abstract 22490.
- Ruane PJ, Tam JT, Libraty DH, et al. Salvage therapy using ritonavir/saquinavir with a non-nucleoside reverse transcriptase inhibitor after prolonged failure with indinavir or ritonavir. Presented at: XIIth International Conference on AIDS; June 1998; Geneva. Abstract 32308.
- Gilmour JG, Gregson DB, Done BL. Nelfinavir-nevirapine rescue therapy for patients failing protease inhibitor based therapy. Presented at: XIIth International Conference on AIDS; June 1998; Geneva. Abstract 22375.
- Murphy RL, Gulick R, Smeaton L, et al. Treatment with indinavir, nevirapine, stavudine and 3TC following therapy with an amprenavir-containing regimen. AIDS. 1998;12\(suppl 4):59. Abstract 0P2.4.
- Lawrence J, Schapiro J, Winters M, et al. Salvage therapy with indinavir plus nevirapine in patients previously treated with two other protease inhibitors and multiple reverse transcriptase inhibitors. Presented at: Fifth Conference on Retroviruses and Opportunistic Infections; February 1998; Chicago. Abstract 422.
- Farthing C, Mess T, Reid C, et al. Ritonavir, saquinavir and nevirapine as a salvage regimen for indinavir or ritonavir resistance. Presented at: XIIth International Conference on AIDS; June 1998; Geneva. Abstract 22356.
- Hirsch MS, Conway B, D’Aquilla RT, et al. Antiretroviral drug resistance testing in HIV infection in adults. JAMA. 1998;279:1984–1991.
- Clevenbergh P, Durant J, Ha!fon P, et al. Persisting long-term benefit of antiretroviral genotypic guided treatment for HIV-infected individuals failing HAART. Antiviral Ther. 1999;4\(suppl 1):42.
- Durant J, Clevenbergh P, Ha!fon P, et al. Can HIV geno-type determination be useful for individualised adaptation of antiretroviral therapy: The VIRADEPT French Study. Presented at: Fourth International Congress on Drug Therapy in HIV Infection; November 1998; Glasgow. Ab-stract 0P7.1.
- Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Merigan TC, CPCRA 046 Study Team. A pilot study of the short-term effects of antiretroviral management based on plasma genotypic antiretroviral resistance testing (GART) in patients failing antiretroviral therapy. Presented at: Sixth Conference on Retroviruses and Opportunistic Infections; February 1999; Chicago. Abstract LB8.
- Hall CS, Raines CP, Barnett SH, Moore RD, Gallant JE. Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-contain-ing regimens. AIDS. 1999;13:1207–1212.
- Rockstroh J, Atfeld M, Kupfer R, et al. Failure of double protease inhibitor therapy as salvage therapy for HIV-infected patients resistant to conventional triple therapy. Presented at: XIIth International Conference on AIDS; June 1998; Geneva. Abstract 22375.
- Kempf D, Rode R, Xu Y, et al. Duration of viral suppressionduring protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS. 1998;12:F9—F14.
- Raboud JM, Montaner JS, Conway B, et al. Suppression of plasma viral load below 20 copies/mL is required to achieve long-term response to therapy. AIDS. 1998;12:1619–1624.